Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Equity Average (2017 - 2026)

Ovid Therapeutics filings provide 10 years of Equity Average readings, the most recent being $164.5 million for Q1 2026.

  • Quarterly Equity Average rose 157.98% to $164.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $164.5 million through Mar 2026, up 157.98% year-over-year, with the annual reading at $99.4 million for FY2025, 27.47% up from the prior year.
  • Equity Average hit $164.5 million in Q1 2026 for Ovid Therapeutics, up from $87.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $172.4 million in Q1 2022 and bottomed at $50.2 million in Q3 2025.
  • Average Equity Average over 5 years is $106.1 million, with a median of $94.5 million recorded in 2023.
  • The largest annual shift saw Equity Average crashed 39.17% in 2025 before it soared 157.98% in 2026.
  • Ovid Therapeutics' Equity Average stood at $137.2 million in 2022, then crashed by 31.07% to $94.5 million in 2023, then decreased by 23.57% to $72.3 million in 2024, then rose by 21.34% to $87.7 million in 2025, then soared by 87.58% to $164.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Equity Average are $164.5 million (Q1 2026), $87.7 million (Q4 2025), and $50.2 million (Q3 2025).